Mukka Proteins Ltd (MUKKA) is currently trading at 24.57 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Mukka Proteins Limited is a diversified marine and sustainable protein company that manufactures fishmeal, fish oil and fish soluble paste, and develops alternate proteins based on Black Soldier Fly insect biotechnology, while also providing waste-to-value and frozen marine products. The company exports to 25+ countries, operates owned facilities in India and Oman, and pursues backward integration and sustainability certifications. Mukka reported a high export orientation with Q1 FY27 export revenue share at 89.5% and an estimated ~25–30% share of India’s fish protein export revenue, giving the company strong global customer stickiness. Coastal asset locations, EU approvals and MarinTrust Improver Programme acceptance position Mukka for premium market access, though the model also means meaningful currency and demand-location exposure. The business is organized into four integrated verticals—Fish Protein, Alternate Proteins (insect biotech), Waste Management/Leachate Solutions, and Frozen & Value-Added products—with material near-term growth catalysts including the ₹474.89 Crore Bengaluru leachate contract, upcoming Oman facility, and recent acquisitions in Delta Marine and Aqua Marine to boost manufacturing and processing capacity. Financially, Mukka’s consolidated FY26 revenues were ₹1,403.6 Crore with profit for the year of ₹57.1 Crore; historical years show pronounced revenue and inventory volatility driven by commodity pricing and raw material cycles. Finance costs rose materially to ₹53.6 Crore in FY26, highlighting leverage and working-capital sensitivity as the company scales international operations and project execution. Sustainability and certification credentials are a strategic differentiator: Mukka reports diversion of 100,000+ tonnes of wet waste from landfills, zero-landfill/leachate operations, carbon-credit approvals amounting to 1,200 TPD, and recognition under the MarinTrust Improver Programme, reinforcing its waste-to-value and traceable-sourcing narrative for global buyers.

Over the past 52 weeks, Mukka Proteins Ltd has traded between a low of ₹18.32 and a high of ₹33.24. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Mukka Proteins Ltd has a market capitalization of approximately 745.50. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Mukka Proteins Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 10.06 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 745.50 Cr, Mukka Proteins Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Mukka Proteins Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Mukka Proteins Ltd is 10.06. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Mukka Proteins reported consolidated PAT of ₹18.63 crore (₹186.34 million) for the quarter ended June 30, 2026.

CESTAT Bengaluru set aside a customs duty demand of ₹152.43 million, holding that the Customs Department failed to prove undervaluation with cogent evidence.

Mukka Proteins has proposed issuing up to 2,00,00,000 convertible warrants on a preferential basis at Rs 23.50 per warrant, aggregating Rs 47 crore.

It is an entirely fresh issue of up to 8 crore equity shares with a face value of Re 1, with no offer-for-sale component mentioned in the provided details.